Kidney dysfunction and deterioration of ejection fraction pose independent risk factors for mortality in implantable cardioverter-defibrillator recipients for primary prevention

Clinical Cardiology

Volumn 35, Issue 9, 2012, Pages 575-579

  Kreuz, Jens ^a   Horlbeck, Fritz ^a   Schrickel, Jan ^a   Linhart, Markus ^a   Fimmers, Rolf ^a   Mellert, Fritz ^b   Nickenig, Georg ^a   Schwab, Jörg Otto ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEFIBRILLATOR; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIMARY PREVENTION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK REDUCTION; SUDDEN DEATH; SYSTOLIC HEART FAILURE;

AGED; ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; KIDNEY DISEASES; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84866264646     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22018     Document Type: Article

References (15)

1. Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346: 877-883.
2. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [published correction appears in N Engl J Med. 2005;352:2146]. N Engl J Med. 2005; 352: 225-237.
3. Buxton AE, Lee KL, Fisher JD, et al. Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease [published correction appears in N Engl J Med. 2000;342:1300]. N Engl J Med. 1999; 341: 1882-1890.
4. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004; 350: 2151-2158.
5. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006; 8: 746-837.
6. Olshansky B, Wood F, Hellkamp AS, et al. SCD-HeFT Investigators. Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J. 2007; 153: 1089-1094.
7. Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial [published correction appears in Circulation. 2010;121:e39]. Circulation. 2009; 120: 2170-2176.
8. Levy WC, Lee KL, Hellkamp AS, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation. 2009; 120: 835-842.
9. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med. 2008; 359: 1009-1017.
10. Olshansky B, Poole JE, Johnson G, et al. SCD-HeFT Investigators. Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. J Am Coll Cardiol. 2008; 51: 1277-1282.
11. Russo AM, Poole JE, Mark DB, et al. Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. J Cardiovasc Electrophysiol. 2008; 19: 720-724.
12. Cuculich PS, Sánchez JM, Kerzner R, et al. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death. Pacing Clin Electrophysiol. 2007; 30: 207-213.
13. Kreuz J, Balta O, Linhart M, et al. An impaired renal function and advanced heart failure represent independent predictors of the incidence of malignant ventricular arrhythmias in patients with an implantable cardioverter/defibrillator for primary prevention. Europace. 2010; 12: 1439-1445.
14. Shewan LG, Coats AJ., Ethics in the authorship and publishing of scientific articles. Int J Cardiol. 2010; 144: 1-2.
15. Amin MS, Fox AD, Kalahasty G, et al. Benefit of primary prevention implantable cardioverter-defibrillators in the setting of chronic kidney disease: a decision model analysis. J Cardiovasc Electrophysiol. 2008; 19: 1275-1280.